ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MabVax Grants Sublicense to Y-mAbs for Neuroblastoma Vaccine
July 11, 2018MabVax Therapeutics has granted to Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer. A third of neuroblastoma patients are diagnosed as infants; and ninety percen -
MabVax Starts Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial
June 29, 2017MabVax Therapeutics announced the first patient has been dosed in the Phase 1 clinical trial evaluating MVT-1075,
Pharma Sources Insight January 2025
